Clinical Trial Update: Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine with or without docetaxel as second-line therapy for metastatic or relapsed, unresectable uterine or soft tissue leiomyosar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Leiomyosarcoma
• Uterine Leiomyosarcoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: UNICANCER | Conditions: Sarcoma | Phase 2 | Status: COMPLETED